NCI CTEP-Approved Trials for January

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.

For further information, contact the principal investigator listed.

Phase I – 10080

Phase I Study of Recombinant Interleukin 15 in Combination with Checkpoint Inhibitors Nivolumab and Ipilimumab in Subjects with Refractory Cancers

National Cancer Institute Developmental Therapeutics Clinic

Chen, A P

(240) 781-3320

Phase I – ABTC-1604

Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters

Adult Brain Tumor Consortium

Alexander, Brian Michael

(617) 732-7560

Phase I – AMC-S007

Longitudinal Quality of Life Study Among Participants with AIDS-Associated Kaposi Sarcoma

Bugando Medical Centre, in Mwanza, Tanzania

AIDS Malignancy Consortium

Schroeder, Kristin Marie

(919) 668-6288

Phase II – 10139

A Randomized Phase 2 Study of Atezolizumab in Combination with Cobimetinib Versus Atezolizumab Monotherapy in Participants with Unresectable Cholangiocarcinoma

JHU Sidney Kimmel Comprehensive Cancer Center LAO

Azad, Nilofer Saba

(410) 614-9169

Phase II – EA5161

Randomized Phase II Clinical Trial of Cisplatin/Carboplatin and Etoposide (CE) Alone or in Combination with Nivolumab as Frontline Therapy for Extensive Stage Small Cell Lung Cancer (ED-SCLC)

ECOG-ACRIN Cancer Research Group

Leal, Ticiana A.

(608) 263-9063

Phase II – EA8153

Cabazitaxel with Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial

ECOG-ACRIN Cancer Research Group

Kyriakopoulos, Christos

(608) 263-0786

Phase II/III – NRG-HN004

Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin

NRG Oncology

Mell, Loren K.

(858) 246-0471

Phase II/III – S1612

A Randomized Phase II/III Trial of “Novel Therapeutics” Versus Azacitidine in Newly Diagnosed Patients with Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS), Age 60 or Older (LEAP: Less-Intense AML Platform Trial)


Michaelis, Laura Christian

(414) 805-1118

Phase Other – AALL17B7-Q

Germline TP53 and ETV6 Mutations in Acute Lymphoblastic Leukemia

Children’s Oncology Group

Yang, Jun J.

(901) 595-2517

Phase Other – AALL17B8-Q

Dissecting the Prognostic Impact of the Pediatric B-ALL Immune Microenvironment Using Single-Cell Approaches

Children’s Oncology Group

Carroll, William L.

(212) 263-9947

Phase Other – WF-30917CD

A Stepped-Care Telehealth Approach to Treat Distress in Rural Cancer Survivors

Wake Forest NCORP Research Base

Danhauer, Suzanne C.

(336) 716-7980